top of page
April 30 - Symposium: Prevention & Treatment of Chronic Disease in the Southeast
PFCD Chair Ken Thorpe & the Partnership to Fight Chronic Disease (PFCD) invites you to join us for this hybrid event focused on an array...
23 hours ago
Partnership to Fight Chronic Disease Statement on Americans’ Access to Anti-Obesity Medications
April 4, 2025 (Washington, D.C.)  – The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the...
Apr 3
New Poll: Majority of Seniors with Medicare Prescription Drug Coverage Remain Unaware of New Payment Options
Results Show Interest in the Medicare Prescription Payment Plan Increases as American Seniors Learn More About It April 3, 2025...
Apr 2
New Research Shows Prescription Drug Affordability Boards Will NOT Benefit Patients
Findings Show Upper Payment Limits (UPLs) Could Increase Costs and Restrict Access to Critical Medicines March 31, 2025 (Washington,...
Mar 30
America has both an obesity and health care cost problem.
Their coexistence is not coincidental. New data application from a recent study further illuminates the relationship between the two...
Feb 21
Biden Administration’s Latest List of Drugs Selected for Medicare Pricing Exacerbates Access and Innovation Risks to People Living with Cancers & Other Chronic Diseases
January 17, 2025 (WASHINGTON, D.C.) Today, the Partnership to Fight Chronic Disease (PFCD) released the following statement in response...
Jan 17
NEW ANALYSIS SHOWS WEIGHT LOSS SAVES EMPLOYERS AND MEDICARE HEALTH CARE COSTS
Modest weight loss among adults with obesity cuts health care spending by 15%, reduces costs across comorbidities December 5, 2024...
Dec 5, 2024
New Poll: Bipartisan Majority Believes Medicare Beneficiaries Should Have Access to FDA-approved Early Alzheimer's Medications the Same Way They Do for All Other Diseases
American voters are willing to pay more to ensure access and want Congress to step in if Medicare continues restricting access to...
Oct 9, 2024
Chronic Disease Patient Groups Call on Congress to Protect Small Molecule Medicine Access and Innovation
September 13, 2024 (Washington, DC) Â The Partnership to Fight Chronic Disease (PFCD) Â released the following statement upon delivery of a...
Sep 12, 2024
NEW DATA ILLUSTRATE HUMAN IMPACTS OF FEWER TREATMENTS RESULTING FROM INFLATION REDUCTION ACT’S PRICE CONTROLS
Case studies highlight peril to treatment advances across several disease states August 14, 2024 (WASHINGTON, DC) The Partnership to...
Aug 14, 2024
Prescription Drug Affordability Board might not deliver savings to patients
By Hannah Pfeiffer and Candace DeMatteis June 5, 2024 Boulder Daily Camera  A group of unelected state officials is pondering a decision...
Jun 4, 2024
New Insurer Perspectives Highlight Considerable Patient Challenges Anticipated from Prescription Drug Affordability Boards
April 2, 2024 (Washington, DC)  Today the Partnership to Fight Chronic Disease (PFCD) released a new white paper, “ Health Plans...
Apr 1, 2024
PRESERVING ACCESS TO SMALL MOLECULE MEDICINES CRITICAL FOR PEOPLE LIVING WITH CHRONIC CONDITIONS
February 1, 2024 (Washington, D.C.) Â Today the Partnership to Fight Chronic Disease (PFCD) applauded Representatives Greg Murphy (R-NC),...
Feb 1, 2024
NEW ANALYSIS FINDS ACCELERATED APPROVAL DRUGS DO NOT DRIVE MEDICAID SPENDING
Findings Published in Health Affairs Forefront Precedent-setting policies to restrict access to accelerated approval drugs do not reduce...
Jun 2, 2022
Compromising Patient Access Is Not a Path Forward for Alzheimer’s Disease
CMS decision harms current and future treatment options for Alzheimer's and other chronic disease populations April 8, 2022 (Washington,...
Apr 7, 2022
NEURODEGENERATIVE DISEASE COSTS EXCEED $655 BILLION A YEAR IN MEDICAL EXPENSES AND ECONOMIC LOSSES
Lack of cures combined with minimal viable treatments compounds increasing health and caregiving costs  May 27, 2021 (WASHINGTON, D.C.)...
May 26, 2021
NEW ANALYSIS OF MEDICAID SPENDING REINFORCES VALUE AND PATIENT IMPACT OF FDA ACCELERATED APPROVAL PATHWAY
Data support preserving access to accelerated approval drugs for the seriously ill  Commentary in the  American Journal of Managed Care...
Mar 29, 2021
bottom of page